

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:16:37 ON 07 AUG 2003

=> file caplus uspatful japio medline europatful biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:17:15 ON 07 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:17:15 ON 07 AUG 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 17:17:15 ON 07 AUG 2003

COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 17:17:15 ON 07 AUG 2003

FILE 'EUROPATFULL' ENTERED AT 17:17:15 ON 07 AUG 2003

COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'BIOSIS' ENTERED AT 17:17:15 ON 07 AUG 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 17:17:15 ON 07 AUG 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s presbyop? and (treat? or therap? or prevent?)

6 FILES SEARCHED...

L1 1334 PRESBYOP? AND (TREAT? OR THERAP? OR PREVENT?)

=> S L1 AND (GLUTATHIONE? OR THIOL?)

L2 23 L1 AND (GLUTATHIONE? OR THIOL?)

=> S L2 AND (energy or heat or sound or enzyme)

L3 15 L2 AND (ENERGY OR HEAT OR SOUND OR ENZYME)

=> s l3 and accommodation

L4 0 L3 AND ACCOMODATION

=>

=> s l3 and ((methyl glutathione) or (s transferase) or thiosulfonate or (thiol transferase) or glutathione or (nicotine(w)adenine(w)dinucleotide(w)phosphate))

L5 10 L3 AND ((METHYL GLUTATHIONE) OR (S TRANSFERASE) OR THIOSULFONAT
E OR (THIOL TRANSFERASE) OR GLUTATHIONE OR (NICOTINE(W) ADENINE(
W) DINUCLEOTIDE(W) PHOSPHATE))

=> d l5 1-10 ibib abs

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

424/449
444
microcapsules

ACCESSION NUMBER: 2002:616201 CAPLUS
 DOCUMENT NUMBER: 137:174935
 TITLE: **Presbyopia treatment** by lens alteration
 INVENTOR(S): Till, Jonathan S.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002110549	A1	20020815	US 2002-50879	20020118
PRIORITY APPLN. INFO.:			US 2001-262423P	P 20010119

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying **energy** to affect a change in the accommodative abilities of the human lens. This invention both **prevents** the onset of **presbyopia** as well as **treats** it. By breaking and/or **preventing** the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule. Biol. acceptable compds. comprise **glutathione** or **thiols** and enzymes such as **glutathione S-transferase** or **thiol** reductase can break disulfide bonds.

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:142552 CAPLUS
 DOCUMENT NUMBER: 136:178019
 TITLE: **Presbyopia treatment** by lens alteration with reducing agents
 INVENTOR(S): Till, Jonathan S.
 PATENT ASSIGNEE(S): Refocus, LLC, USA
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013863	A2	20020221	WO 2001-US25576	20010816
WO 2002013863	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2001083386 A5 20020225 AU 2001-83386 20010816 US 2002025311 A1 20020228 US 2001-930287 20010816 PRIORITY APPLN. INFO.: US 2000-225659P P 20000816 WO 2001-US25576 W 20010816 AB This invention effects a change in the accommodation of the human lens				

affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying external **energy** to affect a change in the accommodative abilities of the human lens. By breaking bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

L5 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:148998 USPATFULL

TITLE: Method and compositions for **treatment** of the aging eye

INVENTOR(S): Petrus, Edward J., Austin, TX, United States

PATENT ASSIGNEE(S): Advanced Medical Instruments, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6573299	B1	20030603
APPLICATION INFO.:	US 1999-399393		19990920 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Fay, Zohreh		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	977		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method for the **prevention** and **treatment** of orbital disorders associated with the aging eye in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-affecting agents which penetrate into the underlying tissues and into the vascular network of the orbit. Another object of this invention is the improvement of age-related changes to the eyelids such as dry skin, wrinkles, keratoses, age spots and pigmented skin lesions. It is a further object of this invention to **prevent** and **treat** cataract formation, glaucoma, diabetic retinopathy and macular degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:330330 USPATFULL

TITLE: Method and composition for rejuvenating cells, tissues organs, hair and nails

INVENTOR(S): Ulrich, Peter C., Portland, OR, UNITED STATES

Fang, Sheng Ding, Mount Kisco, NY, UNITED STATES

Brines, Michael L., Woodbridge, CT, UNITED STATES

Xie, Qiao-Wen, Yonkers, NY, UNITED STATES

Cerami, Anthony, Sleepy Hollow, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002188015	A1	20021212
APPLICATION INFO.:	US 2002-72712	A1	20020207 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-267226P	20010207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DREIER & BARITZ LLP, 499 PARK AVENUE, 20TH FLOOR, NEW	

YORK, NY, 10022

NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
LINE COUNT: 3338

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo **treatment** of organs, cells and tissues and external **treatment** of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:205862 USPATFULL

TITLE: **Presbyopia treatment** by lens alteration

INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110549	A1	20020815
APPLICATION INFO.:	US 2002-50879	A1	20020118 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262423P	20010119 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	515	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying **energy** to affect a change in the accommodative abilities of the human lens. This invention both **prevents** the onset of **presbyopia** as well as **treats** it. By breaking and/or **preventing** the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:92924 USPATFULL

TITLE: Correction of **presbyopia**, other refractive errors and cataract retardation

INVENTOR(S): Myers, Raymond I., Collinsville, IL, UNITED STATES
PATENT ASSIGNEE(S): Second Sight Laser Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049450	A1	20020425
APPLICATION INFO.:	US 2001-897585	A1	20010629 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-821903, filed on 21 Mar 1997, ABANDONED Continuation of Ser. No. US 1999-312518, filed on 14 May 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US. 1996-13791P	19960321 (60)
	US 1997-36904P	19970205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JOHN W KELPER, III, 7733 FORSYTH BLVD., 12TH FLOOR, ST LOUIS, MO, 63105	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	541	

AB The invention consists of methods for **treating** the clear, intact crystalline lens of the eye with high **energy** light such as lasers, for the purpose of correcting **presbyopia**, other refractive errors, and the **prevention** of cataracts. The aim is to change the mass, shape, and/or flexure of the crystalline lens in order to maintain or reestablish the focus of all light onto the macular area.

L5 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:42947 USPATFULL
TITLE: **Presbyopia treatment** by lens alteration

INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025311	A1	20020228
APPLICATION INFO.:	US 2001-930287	A1	20010816 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225659P	20000816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	472	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying external **energy** to affect a change in the accommodative abilities of the human lens. By breaking bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or

lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2001:90126 USPATFULL
TITLE: Multi-phase food & beverage
INVENTOR(S): Zhao, Iris Ginron, Los Angeles, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002269	A1	20010531
APPLICATION INFO.:	US 2000-748775	A1	20001227 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-852238, filed on 6 May 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Iris G. Zhao, c/o Paul D. Inglesby, One Bala Plaza, Suite 213, Bala Cynwyd, PA, 19004		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	2636		

AB A method of making, combining, and using a balanced multi-phase food mixture and a multi-phase beverage made thereof is incorporated into carbonated herb beverage, aerated tea, fast fermented grain drink, amino acid flavored beverage, alcohol soaked cocktail drink, and aerated vegetable beverage. The liquid phase comprises total small molecular mineral and sugar up to 350 mOsm, pH 3.5-7.8, sweetener up to 7 wt %, alcohol up to 3 wt %, protein up to 30 wt %, fiber 20-37 gram per 2000 calories, at least 30% of calories are derived from complex carbohydrate, and up to 5% by volume gas, which will release a meaningful smell when being consumed. The solid phase includes at least 10% by weight plant mix, complex carbohydrate, protein, fat, and a combination thereof. The beverage is natural and balanced referred to physiological body composition for normalizing body composition and fluid metabolism toward optimal body fitness with increased sensory experience and satiety.

L5 ANSWER 9 OF 10 USPATFULL on STN

ACCESSION NUMBER: 1998:122381 USPATFULL
TITLE: **Glutathione** antioxidant eye drops
INVENTOR(S): Hofmann, Robert F., Austin, TX, United States
Bottoni, Don J., Pflugerville, TX, United States
PATENT ASSIGNEE(S): Austin Nutraceutical Corporation, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5817630		19981006
APPLICATION INFO.:	US 1997-820214		19970318 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	350		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An eye drop composition and a method of using the composition to alleviate eye discomfort and for improving lens pliability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER: 95:112205 USPATFULL

TITLE: Method of making intraocular lenses with injectable collagen-based compositions

INVENTOR(S): Kelman, Charles D., New York, NY, United States

DeVore, Dale P., Chelmsford, MA, United States

PATENT ASSIGNEE(S): Autogenesis Technologies, Inc., Acton, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5476515		19951219
APPLICATION INFO.:	US 1993-158019		19931124 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-740838, filed on 6 Aug 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prebilic, Paul B.		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	878		

AB Injectable collagen-based compositions can be used in methods to fill a lens capsular sac, following lens extraction procedures, to form a new intraocular lens. Purified soluble or partially fibrillar collagen may be modified with acylating agents, sulfonating agents or combinations thereof to form a clear, transparent collagen composition having indices of refraction between about 1.2 to 1.6. The modified collagen may be injected into a lens capsular sac to form an intraocular lens (IOL) in situ. The IOL is clear, transparent, resistant to epithelialization and is capable of accommodation. The collagen-based IOL produced by the method of the present invention may remain in its original viscous liquid state or may be polymerized into a soft gel. The collagen-based IOL may be used to replace diseased or natural lens to **treat** cataracts, **presbyopia**, myopia and hyperopia.

FILE 'CAPLUS, USPATFULL, JAPIO, MEDLINE, EUROPATFULL, BIOSIS, EMBASE'
ENTERED AT 17:17:15 ON 07 AUG 2003

L1 1334 S PRESBYOP? AND (TREAT? OR THERAP? OR PREVENT?)
L2 23 S L1 AND (GLUTATHIONE? OR THIOL?)
L3 15 S L2 AND (ENERGY OR HEAT OR SOUND OR ENZYME)
L4 0 S L3 AND ACOOMODATION
L5 10 S L3 AND ((METHYL GLUTATHIONE) OR (S TRANSFERASE) OR THIOSULFO

=> s l5 and (ascorb? or (vitamin E) or (vitamin C))
L6 6 L5 AND (ASCORB? OR (VITAMIN E) OR (VITAMIN C))

=> d l6 1-6 ibib abs

L6 ANSWER 1 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:148998 USPATFULL

TITLE: Method and compositions for **treatment** of the
aging eye

INVENTOR(S): Petrus, Edward J., Austin, TX, United States

PATENT ASSIGNEE(S): Advanced Medical Instruments, Austin, TX, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6573299	B1	20030603
APPLICATION INFO.:	US 1999-399393		19990920 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Fay, Zohreh		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	977		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method for the **prevention** and **treatment** of orbital disorders associated with the aging eye in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-affecting agents which penetrate into the underlying tissues and into the vascular network of the orbit. Another object of this invention is the improvement of age-related changes to the eyelids such as dry skin, wrinkles, keratoses, age spots and pigmented skin lesions. It is a further object of this invention to **prevent** and **treat** cataract formation, glaucoma, diabetic retinopathy and macular degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:205862 USPATFULL

TITLE: **Presbyopia treatment** by lens
alteration

INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110549	A1	20020815
APPLICATION INFO.:	US 2002-50879	A1	20020118 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262423P	20010119 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON, 1500 K STREET, N.W., SUITE 700,
WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying **energy** to affect a change in the accommodative abilities of the human lens. This invention both **prevents** the onset of **presbyopia** as well as **treats** it. By breaking and/or **preventing** the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:42947 USPATFULL

TITLE: **Presbyopia treatment** by lens alteration

INVENTOR(S): Till, Jonathan S., Salem, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025311	A1	20020228
APPLICATION INFO.:	US 2001-930287	A1	20010816 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225659P	20000816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON, 1500 K STREET, N.W., SUITE 700,
WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 472

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention effects a change in the accommodation of the human lens affected by **presbyopia** through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying external **energy** to affect a change in the accommodative abilities of the human lens. By breaking bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2001:90126 USPATFULL

TITLE: Multi-phase food & beverage

INVENTOR(S): Zhao, Iris Ginron, Los Angeles, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002269	A1	20010531

APPLICATION INFO.: US 2000-748775 A1 20001227 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-852238, filed
on 6 May 1997, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Iris G. Zhao, c/o Paul D. Inglesby, One Bala Plaza,
Suite 213, Bala Cynwyd, PA, 19004
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2636

AB A method of making, combining, and using a balanced multi-phase food mixture and a multi-phase beverage made thereof is incorporated into carbonated herb beverage, aerated tea, fast fermented grain drink, amino acid flavored beverage, alcohol soaked cocktail drink, and aerated vegetable beverage. The liquid phase comprises total small molecular mineral and sugar up to 350 mOsm, pH 3.5-7.8, sweetener up to 7 wt %, alcohol up to 3 wt %, protein up to 30 wt %, fiber 20-37 gram per 2000 calories, at least 30% of calories are derived from complex carbohydrate, and up to 5% by volume gas, which will release a meaningful smell when being consumed. The solid phase includes at least 10% by weight plant mix, complex carbohydrate, protein, fat, and a combination thereof. The beverage is natural and balanced referred to physiological body composition for normalizing body composition and fluid metabolism toward optimal body fitness with increased sensory experience and satiety.

L6 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 1998:122381 USPATFULL
TITLE: **Glutathione** antioxidant eye drops
INVENTOR(S): Hofmann, Robert F., Austin, TX, United States
Bottoni, Don J., Pflugerville, TX, United States
PATENT ASSIGNEE(S): Austin Nutraceutical Corporation, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5817630		19981006
APPLICATION INFO.:	US 1997-820214		19970318 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	350		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An eye drop composition and a method of using the composition to alleviate eye discomfort and for improving lens pliability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER: 95:112205 USPATFULL
TITLE: Method of making intraocular lenses with injectable collagen-based compositions
INVENTOR(S): Kelman, Charles D., New York, NY, United States
DeVore, Dale P., Chelmsford, MA, United States
PATENT ASSIGNEE(S): Autogenesis Technologies, Inc., Acton, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5476515		19951219
APPLICATION INFO.:	US 1993-158019		19931124 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-740838, filed on 6 Aug 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prebilic, Paul B.		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	878		

AB Injectable collagen-based compositions can be used in methods to fill a lens capsular sac, following lens extraction procedures, to form a new intraocular lens. Purified soluble or partially fibrillar collagen may be modified with acylating agents, sulfonating agents or combinations thereof to form a clear, transparent collagen composition having indices of refraction between about 1.2 to 1.6. The modified collagen may be injected into a lens capsular sac to form an intraocular lens (IOL) in situ. The IOL is clear, transparent, resistant to epithelialization and is capable of accommodation. The collagen-based IOL produced by the method of the present invention may remain in its original viscous liquid state or may be polymerized into a soft gel. The collagen-based IOL may be used to replace diseased or natural lens to **treat** cataracts, **presbyopia**, myopia and hyperopia.

=>

Day : Thursday

Date: 8/7/2003
Time: 17:27:10 PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = TILL

First Name = JONATHAN

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>60405540</u>	Not Issued	019	08/23/2002	SECURE PAGING DEVICE AND SYSTEM	TILLACK, JONATHAN A.
<u>60348391</u>	Not Issued	020	01/16/2002	REFRACTIVE SURGERY BY LENS ALTERATION	TILL, JONATHAN S.
<u>60330630</u>	Not Issued	020	10/26/2001	REFRACTIVE SURGERY BY LENS ALTERATION	TILL, JONATHAN S.
<u>60312096</u>	Not Issued	020	08/15/2001	REFRACTIVE SURGERY BY LENS ALTERATION	TILL, JONATHAN S.
<u>60277626</u>	Not Issued	020	03/22/2001	PRESBYOPIA TREATMENT BY SCLERAL COMPRESSION	TILL, JONATHAN S.
<u>60262423</u>	Not Issued	020	01/19/2001	PRESBYOPIA TREATMENT BY LENS ALTERATION	TILL, JONATHAN S.
<u>60225659</u>	Not Issued	020	08/16/2000	PRESBYOPIA TREATMENT BY LENS ALTERATION	TILL, JONATHAN S.
<u>60161797</u>	Not Issued	159	10/27/1999	METHODS AND COMPOSITIONS FOR ENHANCING DEVELOPMENTAL POTENTIAL OF OOCYTES	TILLY, JONATHAN
<u>10217259</u>	Not Issued	030	08/12/2002	PROTECTION OF THE FEMALE REPRODUCTIVE SYSTEM FROM NATURAL AND ARTIFICIAL INSULTS	TILLY, JONATHAN L.
<u>10111680</u>	Not Issued	030	12/03/2002	METHODS AND COMPOSITION FOR ENHANCING DEVELOPMENTAL POTENTIAL OF OOCYTES AND ZYGOTES	TILLY, JONATHAN
<u>10102980</u>	Not Issued	041	03/22/2002	PRESBYOPIA TREATMENT BY SCLERAL COMPRESSION	TILL, JONATHAN S.

<u>10050879</u>	Not Issued	030	01/18/2002	PRESBYOPIA TREATMENT BY LENS ALTERATION	TILL, JONATHAN S.
<u>09930287</u>	Not Issued	041	08/16/2001	PRESBYOPIA TREATMENT BY LENS ALTERATION	TILL, JONATHAN S.
<u>09503852</u>	Not Issued	041	02/15/2000	PROTECTION OF THE FEMALE REPRODUCTIVE SYSTEM FROM NATURAL AND ARTIFICIAL INSULTS	TILLY, JONATHAN L.
<u>08646959</u>	<u>5690691</u>	150	05/08/1996	GASTRO-INTESTINAL PACEMAKER HAVING PHASED MULTI-POINT STIMULATION	TILLACK , JONATHAN

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	<input type="text" value="till"/>	<input type="text" value="jonathan"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)